Johnson & Johnson Cash Flow Statement
JNJ / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Johnson & Johnson generated $24.5B in operating cash flow and $19.7B in free cash flow in FY2025. Free cash flow margin was 20.9% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Strong profit margin: 27.3%
- Strong return on equity: 31.7%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $26.8B | $14.1B | $35.2B | $17.9B | $20.9B | $14.7B | $15.1B | $15.3B | $1.3B | $16.5B | $15.4B | $16.3B | $13.8B | $10.9B | $9.7B |
| Depreciation & Amortization | $7.5B | $7.3B | $7.5B | $7.0B | $7.4B | $7.2B | $7.0B | $6.9B | $5.6B | $3.8B | $3.7B | $3.9B | $4.1B | $3.7B | $3.2B |
| Operating Cash Flow | $24.5B | $24.3B | $22.8B | $21.2B | $23.4B | $23.5B | $23.4B | $22.2B | $21.1B | $18.8B | $19.6B | $18.7B | $17.4B | $15.4B | $14.3B |
| Capital Expenditures | $4.8B | $4.4B | $4.5B | $4.0B | $3.7B | $3.3B | $3.5B | $3.7B | $3.3B | $3.2B | $3.5B | $3.7B | $3.6B | $2.9B | $2.9B |
| Free Cash Flow | $19.7B | $19.8B | $18.2B | $17.2B | $19.8B | $20.2B | $19.9B | $18.5B | $17.8B | $15.5B | $16.1B | $15.0B | $13.8B | $12.5B | $11.4B |
| Share Buybacks | $6.0B | $2.4B | $5.1B | $6.0B | $3.5B | $3.2B | $6.7B | $5.9B | $6.4B | $9.0B | $5.3B | $7.1B | $3.5B | $12.9B | $2.5B |
| FCF Margin | 20.9% | 22.3% | 21.4% | 21.5% | 25.1% | 24.4% | 24.3% | 22.7% | 23.3% | 21.6% | 23.0% | 20.2% | 19.4% | 18.5% | 17.5% |